Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.70 |
| ▸ | ALPI | P09923 | 1/20 | 0.70 |
| ▸ | PKM | P14618 | 1/20 | 0.70 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.70 |
| ▸ | XIAP | P98170 | 1/20 | 0.70 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.59 |
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.55 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.55 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | LAP3 | P28838 | 3/20 | 0.50 |
| ▸ | ANPEP | P15144 | 1/20 | 0.50 |
| ▸ | CTSC | P53634 | 1/20 | 0.50 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3208566 | 1.00 | SLC7A5 (0.70) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL7722345 | 1.00 | SLC7A5 (0.70) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL9266010 | 0.83 | SLC7A5 (0.70) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL34465319 | 0.83 | SLC7A5 (0.92) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL23159186 | 0.83 | SLC7A5 (1.00) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL16398196 | 0.83 | SLC7A5 (1.00) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL8119 | 0.83 | SLC7A5 (1.00) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL385804 | 0.83 | SLC7A5 (1.00) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL8118 | 0.83 | SLC7A5 (1.00) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL16398197 | 0.83 | SLC7A5 (1.00) | SLC7A5ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219973-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | MOLECURE S.A. (PL) | 2023-07-13 | — | — | US | claimed |
| WO-2023119233-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | MOLECURE S.A. (PL) | 2023-06-29 | — | — | WO | claimed |
| US-8287835-B2 | Organically functionalized carbon nanocapsule | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2012-10-16 | — | — | US | claimed |
| US-20080160308-A1 | Organically functionalized carbon nanocapsule | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE | 2008-07-03 | — | — | US | claimed |
| EP-1132380-B1 | E-Isomeric fullerene derivatives | CHIANG LONG Y (TW) | 2008-01-23 | — | — | EP | claimed |
| US-7132572-B2 | Fullerene compounds | Chiang, Long Y. (US) | 2006-11-07 | — | — | US | claimed |
| US-6949660-B2 | Chiral (1pyrrolino) fullerene derivatives | SETH NANOTECHNOLOGY, INCORPORATED (US) | 2005-09-27 | — | — | US | claimed |
| US-20050191229-A1 | Fullerene compounds | CHIANG, LONG Y. | 2005-09-01 | — | — | US | claimed |
| US-6790963-B2 | STEREOSPECIFIC PHOTODYANMIC THERAPY SENSITIZERS TO ENHANCE CYTOTOXICITY OF ANTITUMOR AGENTS; FULLEROPYRROLIDINE COMPOUNDS | CHIANG, LONG Y. (TW) | 2004-09-14 | — | — | US | claimed |
| US-6767906-B2 | INHIBIT P34CDC2/CYCLIN BCDC13 KINASE AND PROTEIN TYROSINE KINASE PP60C-SRC AND CAN BE USED FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES, FOR EXAMPLE CHEMOTHERAPY OF TUMOURS OR OSTEOPOROSIS. | NOVARTIS AG (CH) | 2004-07-27 | — | — | US | claimed |
| US-6046361-A | Polyorganofullerenes | SETHNANOTECHNOLOGY, INCORPORATED | 2000-04-04 | — | — | US | claimed |
| US-6020523-A | Polyorganofullerenes | SETHNANOTECHNOLOGY, INCORPORATED | 2000-02-01 | — | — | US | claimed |
| EP-0919520-A2 | Fullernes substituted by several organic groups | Chiang, Long Y. (TW) | 1999-06-02 | — | — | EP | claimed |
| CN-1202896-A | Purine derivatives and processes for their preparation | 诺瓦提斯公司 | 1998-12-23 | — | — | CN | claimed |
| EP-0874846-A1 | PURINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | Novartis AG (CH) | 1998-11-04 | — | — | EP | claimed |
| WO-1997016452-A1 | PURINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 1997-05-09 | — | — | WO | claimed |
| EP-0236164-B1 | DERIVATIVES OF N-ALPHA-ARYLSOLFONYLAMINOACYL P-AMIDINO-PHENYLALANINAMIDES, PROCESS FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND THEIR INTERMEDIATES | SANOFI (FR) | 1990-09-12 | — | — | EP | claimed |
| EP-0236164-A1 | Derivatives of N-alpha-arylsolfonylaminoacyl p-amidino-phenylalaninamides, process for their preparation, their use as medicaments and their intermediates | SANOFI (FR) | 1987-09-09 | — | — | EP | claimed |
| EP-0071926-B1 | NEW RIBOFURANURONIC ACID DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-10-08 | — | — | EP | claimed |
| EP-0071926-A1 | New ribofuranuronic acid derivatives, processes for preparation thereof and pharmaceutical compositions thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-02-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219973-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | USP7, USP28, USP1 | SLC7A5 3588/4885ALPI 2368/4885PKM 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.